Biogen Signs Up Avonex Distributors

18 August 1996

- Biogen has signed European distribution agreements with Astra and Schering-Plough for its multiple sclerosis treatment Avonex (interferon beta-1a). Once the drug is approved in Europe, Astra will have rights to market it in Nordic countries, while S-P gains distribution rights in Spain. Biogen is also intending to self-market the drug in certain European markets, including France, Germany, the Benelux countries and the UK. It already has distribution deals with Dompe in Italy and CSL in Australia and New Zealand.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight